Navigation Links
The Production and Marketing of IBS Drug Halted by the Chinese Government

The Chinese Food and Drug administration has put a halt to the production and marketing of Novratis AGs Zelnorm Drug, for irritable bowel syndrome, as the risk associated with it outweighs the benefits. The patients are asked to stop taking the medication.

The Chinese Drug watchdog posted a statement on its website warning risks of Zelnorm outweigh the possible benefits for some patients based on analyses from home and abroad." It is believed that the drug is linked to an increased risk of heart attacks and strokes.

The National Center for Adverse Drug Reaction Monitoring has received 98 reports of adverse reactions concerning Zelnorm since 2003 when the medicine was introduced to the Chinese market. The adverse reaction involved instances of Diarrhea and Nausea. One reported case was of abnormally fast heartbeat and another case of low blood pressure.

The Novrotis Drug was manufactured by three companies in China and is available in more than 20 provinces with thousands of users.

A review of data from 18,000 patients taking the medicine conducted by Novartis AG, Switzerland's largest drug maker, showed that a significant number had experienced cardiovascular problems. The company had complied with request from The American food and drug administration to with the Zelnorm drug from the market as it was linked with increased risk of heart attack, stroke and chest pain that can become a heart attack, the AP reported.

"We have announced this morning that we are complying with a request from the local authority to suspend the marketing and sales activity of (Zelnorm) in China," Novartis spokeswoman Corinne Hoff said. "More than 85 percent of our sales were in the U.S," she said. "I cannot give you the sales figures for China, but it's not significant," Hoff said.


'"/>




Page: 1

Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Tea Found To Boost Insulin Production And Prevent Cataract
3. Conroy’s May Not Be Permitted To Resume Production Soo
4. Massive Production Of Bird Flu Vaccine To Be Initiated In China
5. Chugai Pharmaceutical To Initiate Domestic Production Of Bird Flu Vaccine
6. Coca Cola To Enhance Production Of Diet Coke
7. Natco Pharma Commences Production At Dehradun Unit
8. New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine
9. ABCB6 Is Key to Production of Heme in Hemoglobin
10. Drug Boosts Platelet Production, Reversing Immune Thrombocytopenic Purpura
11. High-Tech Microbes Bolsters Natural Sweetener Production
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management ... begun to serve as its new executive director. Mr. Still was selected through a ... , “Bob, as he is known to our members, has been a part ...
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of ... medical professionals in the country to sit on the 2017 National Advisory Board for ... 2 years Dr. Harper helped propel the clinic from a small start-up to number ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... March 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: ... addressing cancer and other unmet medical needs, announced ... for Cancer Research annual meeting.  The first poster ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 ... poster to be presented on April 4 is ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... -- A recent study at Shriners Hospitals for Children – ... country dedicated to the treatment of pediatric burns and ... Surfacide Helios ® UV-C Disinfection System is ... not killed by the EVS (manual) cleaning process alone." ... Association,s 49th Annual Meeting in Boston ...
Breaking Medicine Technology: